60 Degrees Pharma (Nasdaq: SXTP) Q2 2025: Supply issue cut revenue, profits rose from cash-pay sales; $1.97M cash extends runway to Mar 2026.
Related Questions
How does the Q2 2025 performance compare to key competitors in the same therapeutic area?
What specific supply issue caused the revenue decline and is it resolved?
How much did revenue decline compared to the same quarter last year?
What were the exact profit figures and how do they compare to analyst expectations?
How does the cash-pay sales increase affect the company's cash flow outlook?
Is the $1.97 million cash balance sufficient for operational needs beyond March 2026?
What are the company’s plans to mitigate future supply chain disruptions?
What guidance does management provide for Q3 and the full year 2025?
Are there any upcoming regulatory milestones or product approvals that could impact revenue?
How does the current valuation (PE, EV/EBITDA) compare after the earnings release?
How might this earnings release influence analyst ratings and target price adjustments?
What is the impact on the company’s capital structure and debt levels?